Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
8.27
-0.36 (-4.17%)
At close: Jan 30, 2026, 4:00 PM EST
8.32
+0.05 (0.60%)
After-hours: Jan 30, 2026, 7:11 PM EST
CRBP Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
28
Market Cap
153.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 881.71K | -3.06M | -77.61% |
| Dec 31, 2020 | 3.94M | -32.21M | -89.11% |
| Dec 31, 2019 | 36.14M | 31.32M | 649.51% |
| Dec 31, 2018 | 4.82M | 2.38M | 97.62% |
| Dec 31, 2017 | 2.44M | 528.77K | 27.66% |
| Dec 31, 2016 | 1.91M | 1.26M | 194.80% |
| Dec 31, 2015 | 648.38K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 113.34M |
| Zentalis Pharmaceuticals | 26.87M |
| Opus Genetics | 14.63M |
| Prelude Therapeutics | 10.50M |
| Rani Therapeutics Holdings | 1.20M |
| Molecular Partners AG | 856.30K |
CRBP News
- 16 days ago - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 27 days ago - Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript - Seeking Alpha
- 7 weeks ago - Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss - GlobeNewsWire
- 7 weeks ago - Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 - GlobeNewsWire
- 3 months ago - Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Corbus Pharmaceuticals: Data Update And Fundraising Efforts Do Not Diminish The Thesis - Seeking Alpha
- 3 months ago - Corbus Pharmaceuticals Announces Pricing of Public Offering - GlobeNewsWire